Cargando…

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study

BACKGROUND: In our previous study, we investigated the efficacy of ipragliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor on diabetic nephropathy in patients with type 2 diabetes and demonstrated that ipragliflozin significantly improved diabetic nephropathy in addition to reducing HbA1c a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Daisuke, Inoue, Kazuyuki, Sumita, Takashi, Hamaguchi, Keiko, Kaneko, Kimie, Yanagisawa, Morifumi, Inukai, Kouichi, Inoue, Ikuo, Noda, Mitsuhiko, Shimada, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089574/ https://www.ncbi.nlm.nih.gov/pubmed/30116437 http://dx.doi.org/10.14740/jocmr3491w

Ejemplares similares

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects
por: Ito, Daisuke, et al.
Publicado: (2015)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Bodyweight threshold for sudden onset of ketosis might exist in ketosis‐prone type 2 diabetes patients
por: Satomura, Atsushi, et al.
Publicado: (2019)

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
por: Ito, Daisuke, et al.
Publicado: (2015)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial
por: Tanaka, Masashi, et al.
Publicado: (2020)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Weight control before and during pregnancy for patients with gestational diabetes mellitus
por: Yasuda, Shigemitsu, et al.
Publicado: (2019)

Administration of thiamazole for Graves’ disease might trigger the onset of type 1 diabetes
por: Mizutani, Gen, et al.
Publicado: (2018)

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study
por: Tobe, Kazuyuki, et al.
Publicado: (2019)

Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
por: Nakamura, Ichiro, et al.
Publicado: (2021)

Intrinsic insulin secretion capacity might be preserved by discontinuing anti‐programmed cell death protein 1 antibody treatment in ‘anti‐programmed cell death protein 1 antibody‐induced’ fulminant type 1 diabetes
por: Sakai, Gota, et al.
Publicado: (2018)

Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
por: Bando, Yukihiro, et al.
Publicado: (2016)

Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
por: Nakamura, Ichiro, et al.
Publicado: (2019)

Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
por: Nakamura, Ichiro, et al.
Publicado: (2021)

Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
por: Nakamura, Ichiro, et al.
Publicado: (2021)

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
por: Inoue, Hideka, et al.
Publicado: (2019)

Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
por: Nakamura, Ichiro, et al.
Publicado: (2021)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Luminal plant sterol promotes brush border membrane-to-lumen cholesterol efflux in the small intestine
por: Nakano, Takanari, et al.
Publicado: (2018)

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018)

Insulin2(Q104del) (Kuma) mutant mice develop diabetes with dominant inheritance
por: Sakano, Daisuke, et al.
Publicado: (2020)

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
por: Ueno, Hiroaki, et al.
Publicado: (2018)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
por: Kishimoto, Shinji, et al.
Publicado: (2023)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

Diabetes mellitus defined by hemoglobin A1c value: Risk characterization for incidence among Japanese subjects in the JPHC Diabetes Study
por: Kato, Masayuki, et al.
Publicado: (2011)

Burden of cancer associated with type 2 diabetes mellitus in Japan, 2010–2030
por: Saito, Eiko, et al.
Publicado: (2016)

Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome
por: Yasuda, Shigemitsu, et al.
Publicado: (2020)

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Urinary Fetuin-A Is a Novel Marker for Diabetic Nephropathy in Type 2 Diabetes Identified by Lectin Microarray
por: Inoue, Kentaro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qktg50dm4gimb97qd6jum5ahbv